Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers

Posted On: 2020-03-27 09:50:28

Biocon Ltd. and Biocon Biologics have activated business continuity plans across their functions to prepare for unforeseen events in light of the evolving COVID-19 situation and to meet the needs of patients, partners, customers and other stakeholders who depend on our products.

As a global Company, we have presence across India, UAE, Malaysia, Singapore, Europe, U.S. and are adjusting our operations to fully comply with regulations issued by respective national governments. In India, home to the largest part of our workforce, the government announced a 21-day nationwide lockdown on Tuesday, March 24, 2020, but permitted "essential services" such as manufacturing of pharmaceuticals to continue. Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements.

Chairperson Kiran Mazumdar-Shaw said, "As a globally recognized biopharmaceuticals company engaged in innovative science to develop new drugs and manufacturing life-saving therapies, we have a significant role to play in the global pharma ecosystem. At the same time, we also have a role to play in the national response to the COVID-19 threat. Indian Prime Minister Narendra Modi's call for a 21-day nationwide lockdown is a good move to stop social transmission of the novel coronavirus. We are supporting local health officials and government leaders as they work to mitigate the disease. Now is not the time to step away from our duties but to step forward to play our part and serve the nation."

Biocon and its subsidiary Biocon Biologics are fully supportive of the Indian government's decision and is aligned with the authorities to address this national emergency. We had already created a task force to deal with this pandemic situation.

Since we are involved in manufacturing of essential drugs, we are assessing the impact of the lockdown on our ability to continue with manufacturing operations of essential pharmaceuticals, biopharmaceuticals and APIs in order to meet our commitments to patients, customers and partners.

While supply chain disruptions and impaired mobility due to lockdowns have a direct bearing on our operations, we are working to minimise disruption to production schedules and supply of drugs to our customers and partners.

We do anticipate delayed deliveries for some products due to partial shutdown and changes in production schedule and restriction of goods movement within and outside India. We are engaging with our vendors to secure supplies of various raw materials but they are also in a similar situation. The current inventory of most of our raw materials is estimated to last us for the next few months.

We are committed to patient safety for all clinical studies currently underway, and will continue to enable drug supply for ongoing clinical trials to ensure patients receive uninterrupted treatment and care as a part of the trials.

In line with our commitment to provide a safe working environment to our employees, we have significantly reduced the number of people in our facilities to only those who are required to carry out manufacturing and quality operations based on planned production schedules. All other employees are either staying back or are working remotely from home.

All necessary measures to slow the spread of COVID-19 and help in 'flattening of the curve' have been taken. In addition to promoting good hygiene and introducing shift working and working from home, national and international business travel for our employees have been stopped and virtual meetings are encouraged, dining facilities have been segregated and seating density reduced, company transport has been scheduled to reduce the number of travellers per vehicle. A dedicated intranet site provides employees with important information related to COVID-19 guidelines and status updates.

These precautionary measures will remain in effect until April 15, 2020.

We remain committed to the health and safety of our employees and their families, as well as, business continuity to safeguard the interests of our patients, partners, customers and other stakeholders.

Shares of BIOCON LTD. was last trading in BSE at Rs.282.3 as compared to the previous close of Rs. 272.05. The total number of shares traded during the day was 145125 in over 3613 trades.

The stock hit an intraday high of Rs. 284.6 and intraday low of 270.7. The net turnover during the day was Rs. 40552800.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

PNB Gilts Ltd reports Q4 FY2020 PAT of Rs. 99.01 crore

Igarashi Motors India Ltd posts Q4 FY20 net profit of Rs. 2.17 crore

Ashok Leyland launches AVTR - its BS-VI compliant Modular Trucks

PNB Gilts Ltd board recommends final dividend of Rs. 3 for FY2019-20

Lupin and Mylan receive European marketing authorization for Nepexto®, Biosimilar Etanercept

Igarashi Motors India Ltd board recommends dividend of Rs. 1.20

APL Apollo Unveils 'Apollo Fencing Solution' that Blends Protection with Aesthetics

NIIT Ltd Q4 consolidated PAT at Rs. 0.59 crore

Tourism Finance Corporation of India Ltd Q4 PAT falls to Rs. 12.17 crore

Let's Do It India Network in collaboration with Finolex Pipes

Newgen Unveils new AI and ML-based Document Classification Service

Mittal Lifestyle Ltd Posts Excellent Results for Year Ended March 2020

IOL Chemicals & Pharmaceuticals Ltd board to consider Q4, FY20 results on June 12, 2020

Safari Industries India Ltd Q4 FY20 consolidated PAT at Rs. 4.68 crore

Jindal Stainless Limited export orders rebound in May-June period

IndusInd Bank launches India's first mobile app based facility for opening current accounts in a paperless manner

TCS Recognized as a Leader in IDC MarketScape for Business and Industrial IoT Consulting and System Integration Services

Cyient Appoints Meenu Bagla as Vice President and Chief Marketing Officer

Vinati Organics Ltd board to consider Q4, FY20 results, final dividend on June 13, 2020

Maruti Suzuki introduces 'Health and Hygiene' range of Genuine Accessories

DCB Bank announces revised External Benchmark Linked Rate from June 5, 2020

Neogen Chemicals adds another marquee investor to its list of shareholders as promoters divest 11.26 lakh shares

Indiabulls Ventures Ltd allots 2,69,09,089 shares

Dishman Carbogen Amcis Ltd Q4 consolidated PAT at Rs. 71.99 crore

Reliance Industries' rights issue receives overwhelming response with subscription of 1.59 times

IOB updates Moody's rating

Moody's downgrades rating of Powergrid

Oriental Hotels Ltd board recommends final dividend of Rs. 0.20 for FY20

IBM and Persistent Systems to accelerate IBM Cloud Pak Deployment and Core IT Modernization for Enterprises

Duncan Engineering Ltd Q4 loss at Rs. 0.80 crore

De Nora India Ltd Q4 PAT at Rs. 2.20 crore

DISA India Ltd Q4 consolidated loss at Rs. 1.63 crore

DCM Shriram Ltd consolidated Q4 FY2020 PAT at Rs. 207.38 crore

Yash Chemex Ltd posts consolidated PAT of Rs. 1.05 crore in Q4 FY20

MAS Financial Services Ltd reports Rs. 35.67 crore consolidated PAT in Q4 FY20

DCM Shriram Ltd approves investment of Rs. 42.40 crores

DISA India Limited board approves final dividend of Rs. 2.50

Vesuvius India Ltd Q1 CY20 PAT drops to Rs. 18.65 crore

Aurobindo Pharma Ltd Q4 consolidated PAT climbs to Rs. 998.57 crore

Cholamandalam Investment and Finance Company Ltd Q4 consolidated PAT slides to Rs. 42.45 crore

JSPL records a 28% YoY rise in monthly Steel sales volumes with the revival of domestic demand

Moody's downgrade HUDCO's rating

Moody's revise credit rating of GAIL India Ltd

Zensar supports Destination: Home in the US for COVID-19 relief initiatives

Gennex Laboratories Limited receives WHO GMP certificate

EESL and GAIL sign an MoU for Trigeneration projects

CRISIL reaffirms long-term bank facilities rating of TNPL

Sinclairs Hotels Ltd fixes June 18, 2020 as record date for stock split

Religare Enterprises Becomes External Debt-free

Moddys downgrades rating of HPCL

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019